Search details
1.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33357420
2.
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Lancet Oncol
; 18(7): 917-928, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28592386
Results
1 -
2
de 2
1
Next >
>>